Laropiprant

Laropiprant is a potent and selective DP receptor antagonist with Ki values of 0.57 nM and 2.95 nM for DP receptor and TP Receptor, respectively[1][2][3].

Product Specifications

CAS Number

[571170-77-9]

Product Name Alternative

MK-0524

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Prostaglandin Receptor

Type

Reference compound

Related Pathways

GPCR/G Protein

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology; Endocrinology

Assay Protocol

https://www.medchemexpress.com/laropiprant.html

Purity

99.34

Solubility

DMSO : ≥ 100 mg/mL

Smiles

O=S(C1=CC(F)=CC2=C1N(C3=C2CC[C@@H]3CC(O)=O)CC4=CC=C(Cl)C=C4)(C)=O

Molecular Formula

C21H19ClFNO4S

Molecular Weight

435.90

Precautions

H302, H312, H332

References & Citations

[1]Labrecque P, et, al. Inverse agonist and pharmacochaperone properties of MK-0524 on the prostanoid DP1 receptor. PLoS One. 2013 Jun 10;8 (6) :e65767.|[2]Sturino CF, et, al. Discovery of a potent and selective prostaglandin D2 receptor antagonist, [ (3R) -4- (4-chloro-benzyl) -7-fluoro-5- (methylsulfonyl) -1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524) . J Med Chem. 2007 Feb 22;50 (4) :794-806.|[3]Chang SW, et, al. The pharmacokinetics and disposition of MK-0524, a Prosglandin D2 Receptor 1 antagonist, in rats, dogs and monkeys. Xenobiotica. 2007 May;37 (5) :514-33.